BELN supplementation also improves liver dysfunction and insulin resistance in NAFLD, which is accompanied by a reduction in AST and ALT levels and fat deposition as well as a downregulation in acetyl-CoA carboxylase 1 (ACC1) and fatty acid synthase (FAS) expression (252). This evidence concerns the gene ACACA and metabolic dysfunction-associated steatotic liver disease.